Paclitaxel- or sirolimus-coated balloons used for ArterioVEnous fistulas-2 (PAVE-2): study protocol for a randomised controlled trial to determine the efficacy of paclitaxel- or sirolimus-coated balloons in arteriovenous fistulas used for haemodialysis.
Humans
Paclitaxel
/ administration & dosage
Renal Dialysis
Arteriovenous Shunt, Surgical
/ adverse effects
Sirolimus
/ administration & dosage
Vascular Patency
Multicenter Studies as Topic
Randomized Controlled Trials as Topic
Coated Materials, Biocompatible
Treatment Outcome
Time Factors
Angioplasty, Balloon
/ instrumentation
Vascular Access Devices
Cardiovascular Agents
/ administration & dosage
Graft Occlusion, Vascular
/ etiology
Angioplasty
Arteriovenous fistula
Fistuloplasty
Haemodialysis
Paclitaxel
Sirolimus
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
31 Oct 2024
31 Oct 2024
Historique:
received:
12
08
2024
accepted:
23
09
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
epublish
Résumé
In view of the conflicting results from previous studies, the benefit of paclitaxel-coated balloons for arteriovenous fistulas is uncertain and equipoise remains. Although an industry-led trial testing the efficacy of sirolimus-coated balloons in AVFs is in progress, the benefit of sirolimus-coated balloons for arteriovenous fistulas is currently unknown. The purpose of this trial is to compare the efficacy of additional paclitaxel-coated or sirolimus-coated balloons on outcomes after a plain balloon fistuloplasty to preserve the patency of arteriovenous fistulae used for haemodialysis. The study design is a multicentre randomised controlled trial. Following a successful plain balloon fistuloplasty, participants will be randomised to further treatment with a paclitaxel-coated balloon, a sirolimus-coated balloon, or an uncoated control balloon. We will recruit 642 patients, each with one or two treatment segments, over a 3-year period. Patients will remain in the trial and be followed up for 1 year. The primary endpoint is time to loss of treatment segment primary patency. Cox-proportional hazards models will be used to estimate hazard ratios for the time to loss of treatment segment primary patency for each treatment group relative to the control group. Analysis of the primary endpoint will be based on treatment segments rather than participants and a shared frailty will be estimated to account for the clustering of treatment segments within patients. Secondary endpoints are time to loss of primary patency at any treatment segment; time to end of access circuit primary patency; time to AVF abandonment; number of radiological or surgical interventions; adverse events; intima-media thickness and degree of stenosis at 3 months on ultrasound; and patient quality of life assessed by EQ-5D-5L and VASQoL. The three-armed design in this proposal will provide an answer on the efficacy of both paclitaxel- and sirolimus-coated balloons in the same trial. This trial is likely to provide a clear answer regarding the efficacy of drug-coated balloons for arteriovenous fistulas. ISRCTN ISRCTN40182296. Registered on 4 August 2023.
Sections du résumé
BACKGROUND
BACKGROUND
In view of the conflicting results from previous studies, the benefit of paclitaxel-coated balloons for arteriovenous fistulas is uncertain and equipoise remains. Although an industry-led trial testing the efficacy of sirolimus-coated balloons in AVFs is in progress, the benefit of sirolimus-coated balloons for arteriovenous fistulas is currently unknown. The purpose of this trial is to compare the efficacy of additional paclitaxel-coated or sirolimus-coated balloons on outcomes after a plain balloon fistuloplasty to preserve the patency of arteriovenous fistulae used for haemodialysis.
METHODS
METHODS
The study design is a multicentre randomised controlled trial. Following a successful plain balloon fistuloplasty, participants will be randomised to further treatment with a paclitaxel-coated balloon, a sirolimus-coated balloon, or an uncoated control balloon. We will recruit 642 patients, each with one or two treatment segments, over a 3-year period. Patients will remain in the trial and be followed up for 1 year. The primary endpoint is time to loss of treatment segment primary patency. Cox-proportional hazards models will be used to estimate hazard ratios for the time to loss of treatment segment primary patency for each treatment group relative to the control group. Analysis of the primary endpoint will be based on treatment segments rather than participants and a shared frailty will be estimated to account for the clustering of treatment segments within patients. Secondary endpoints are time to loss of primary patency at any treatment segment; time to end of access circuit primary patency; time to AVF abandonment; number of radiological or surgical interventions; adverse events; intima-media thickness and degree of stenosis at 3 months on ultrasound; and patient quality of life assessed by EQ-5D-5L and VASQoL.
DISCUSSION
CONCLUSIONS
The three-armed design in this proposal will provide an answer on the efficacy of both paclitaxel- and sirolimus-coated balloons in the same trial. This trial is likely to provide a clear answer regarding the efficacy of drug-coated balloons for arteriovenous fistulas.
TRIAL REGISTRATION
BACKGROUND
ISRCTN ISRCTN40182296. Registered on 4 August 2023.
Identifiants
pubmed: 39482722
doi: 10.1186/s13063-024-08502-1
pii: 10.1186/s13063-024-08502-1
doi:
Substances chimiques
Paclitaxel
P88XT4IS4D
Sirolimus
W36ZG6FT64
Coated Materials, Biocompatible
0
Cardiovascular Agents
0
Types de publication
Journal Article
Clinical Trial Protocol
Langues
eng
Sous-ensembles de citation
IM
Pagination
734Informations de copyright
© 2024. The Author(s).
Références
Viecelli AK, Howell M, Tong A, Teixeira-Pinto A, O’Lone E, Ju A, et al. Identifying critically important vascular access outcomes for trials in haemodialysis: an international survey with patients, caregivers and health professionals. Nephrol Dial Transplant. 2019;35(4):657–68.
doi: 10.1093/ndt/gfz148
The Vascular Priority Setting Partnership. Setting the agenda for UK vascular research. JVascSocGBIrel. 2021;1(1):1–31.
https://ukkidney.org/sites/renal.org/files/23rd_UKRR_ANNUAL_REPORT.pdf
Lok CE. Fistula interventions: less is more. J Am Soc Nephrol. 2019;30(11):2040–2.
doi: 10.1681/ASN.2019090952
pubmed: 31611241
pmcid: 6830789
Manou-Stathopoulou S, Robinson EJ, Harvey JJ, Karunanithy N, Calder F, Robson MG. Factors associated with outcome after successful radiological intervention in arteriovenous fistulas: a retrospective cohort. J Vasc Access. 2019;20(6):716–24.
doi: 10.1177/1129729819845991
pubmed: 31084389
pmcid: 6856953
Rajan DK, Bunston S, Misra S, Pinto R, Lok CE. Dysfunctional autogenous hemodialysis fistulas: outcomes after angioplasty–are there clinical predictors of patency? Radiology. 2004;232(2):508–15.
doi: 10.1148/radiol.2322030714
pubmed: 15286321
Manninen HI, Kaukanen ET, Ikaheimo R, Karhapaa P, Lahtinen T, Matsi P, et al. Brachial arterial access: endovascular treatment of failing Brescia-Cimino hemodialysis fistulas–initial success and long-term results. Radiology. 2001;218(3):711–8.
doi: 10.1148/radiology.218.3.r01mr38711
pubmed: 11230644
Heye S, Maleux G, Vaninbroukx J, Claes K, Kuypers D, Oyen R. Factors influencing technical success and outcome of percutaneous balloon angioplasty in de novo native hemodialysis arteriovenous fistulas. Eur J Radiol. 2012;81(9):2298–303.
doi: 10.1016/j.ejrad.2011.09.004
pubmed: 21955605
Aktas A, Bozkurt A, Aktas B, Kirbas I. Percutaneous transluminal balloon angioplasty in stenosis of native hemodialysis arteriovenous fistulas: technical success and analysis of factors affecting postprocedural fistula patency. Diagn Interv Radiol. 2015;21(2):160–6.
doi: 10.5152/dir.2014.14348
pubmed: 25698092
pmcid: 4463311
Turmel-Rodrigues L, Pengloan J, Baudin S, Testou D, Abaza M, Dahdah G, et al. Treatment of stenosis and thrombosis in haemodialysis fistulas and grafts by interventional radiology. Nephrol Dial Transplant. 2000;15(12):2029–36.
doi: 10.1093/ndt/15.12.2029
pubmed: 11096150
Bountouris I, Kristmundsson T, Dias N, Zdanowski Z, Malina M. Is repeat PTA of a failing hemodialysis fistula durable? Int J Vasc Med. 2014;2014: 369687.
pubmed: 24587906
Ng LJ, Chen F, Pisoni RL, Krishnan M, Mapes D, Keen M, et al. Hospitalization risks related to vascular access type among incident US hemodialysis patients. Nephrol Dial Transplant. 2011;26(11):3659–66.
doi: 10.1093/ndt/gfr063
pubmed: 21372255
CDC. Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients- -United States, 2005. MMWR Morb Mortal Wkly Rep. 2007;56(9):197–9.
Crowley L, MacNeill S, Methven S, Nsonwu O, Davies J, Caskey FJ, et al. UK Renal Registry 19th Annual Report: chapter 10 epidemiology of reported infections in patients receiving dialysis in England between January 2015 and December 2015: a joint report from Public Health England and the UK Renal Registry. Nephron. 2017;137(Suppl 1):251–8.
doi: 10.1159/000481372
pubmed: 28930729
Poinen K, Quinn RR, Clarke A, Ravani P, Hiremath S, Miller LM, et al. Complications from tunneled hemodialysis catheters: a Canadian observational cohort study. Am J Kidney Dis. 2019;73(4):467–75.
doi: 10.1053/j.ajkd.2018.10.014
pubmed: 30642607
Luo C, Liang M, Liu Y, Zheng D, He Q, Jin J. Paclitaxel coated balloon versus conventional balloon angioplasty in dysfunctional dialysis arteriovenous fistula: a systematic review and meta-analysis of randomized controlled trials. Ren Fail. 2022;44(1):155–70.
doi: 10.1080/0886022X.2022.2029487
pubmed: 35166168
Trerotola SO, Lawson J, Roy-Chaudhury P, Saad TF, Trial LAC. Drug coated balloon angioplasty in failing AV fistulas: a randomized controlled trial. Clin J Am Soc Nephro. 2018;13(8):1215–24.
doi: 10.2215/CJN.14231217
Lookstein RA, Haruguchi H, Ouriel K, Weinberg I, Lei L, Cihlar S, et al. Drug-coated balloons for dysfunctional dialysis arteriovenous fistulas. N Engl J Med. 2020;383(8):733–42.
doi: 10.1056/NEJMoa1914617
pubmed: 32813949
Karunanithy N, Robinson EJ, Ahmad F, Burton JO, Calder F, Coles S, et al. A multicenter randomized controlled trial indicates that paclitaxel-coated balloons provide no benefit during angioplasty of arteriovenous fistulas. Kidney Int. 2021;100(2):447–56.
doi: 10.1016/j.kint.2021.02.040
pubmed: 33781793
Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 1995;76(3):412–7.
doi: 10.1161/01.RES.76.3.412
pubmed: 7532117
Roy-Chaudhury P, Arend L, Zhang J, Krishnamoorthy M, Wang Y, Banerjee R, et al. Neointimal hyperplasia in early arteriovenous fistula failure. Am J Kidney Dis. 2007;50(5):782–90.
doi: 10.1053/j.ajkd.2007.07.019
pubmed: 17954291
Schachner T, Zou YP, Oberhuber A, Tzankov A, Mairinger T, Laufer G, et al. Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts. Ann Thorac Surg. 2004;77(5):1580–5.
doi: 10.1016/j.athoracsur.2003.10.008
pubmed: 15111146
Fereydooni A, Guo XJ, Isaji T, Gorecka J, Ono S, Nassiri N, et al. Rapamycin alters venous remodeling to improve arteriovenous fistula patency. J Vasc Surg. 2019;69(6):E265–365.
doi: 10.1016/j.jvs.2019.04.403
Tang TY, Soon SXY, Yap CJQ, Chan SL, Tan RY, Pang SC, et al. Early (6 months) results of a pilot prospective study to investigate the efficacy and safety of sirolimus coated balloon angioplasty for dysfunctional arterio-venous fistulas: MAgicTouch Intervention Leap for Dialysis Access (MATILDA) Trial. PLoS ONE. 2020;15(10):e0241321.
doi: 10.1371/journal.pone.0241321
pubmed: 33108398
pmcid: 7591053
Tang TY, Soon SXY, Yap CJQ, Chan SL, Choke ETC, Chong TT. Utility of sirolimus coated balloons for salvaging dysfunctional arteriovenous fistulae: one year results from the MATILDA trial. Eur J Vasc Endovasc. 2021;62(2):316–7.
doi: 10.1016/j.ejvs.2021.04.014
Tang TY, Chong TT, Yap CJQ, Soon SXY, Chan SL, Tan RY, et al. Intervention with selution SLR agent balloon for endovascular latent limus therapy for failing AV fistulas (ISABELLA) trial: protocol for a pilot clinical study and pre-clinical results. J Vasc Access. 2021;24(2):289–99.
doi: 10.1177/11297298211020867
pubmed: 34219511
pmcid: 10021111
Tang TY, Soon SX, Yap CJ, Tan RY, Pang SC, Patel A, et al. Endovascular salvage of failing arterio-venous fistulas utilising sirolimus eluting balloons: six months results from the ISABELLA trial. J Vasc Access. 2021;24(5):1008–17.
doi: 10.1177/11297298211067059
pubmed: 34965764
Tang TY, Yap CJ, Soon SX, Tan RY, Pang SC, Patel A, et al. Utility of the selution SLR sirolimus eluting balloon to rescue failing arterio-venous fistulas - 12 month results of the ISABELLA Registry from Singapore. Cvir Endovasc. 2022;5(1):8.
doi: 10.1186/s42155-022-00287-1
pubmed: 35103894
pmcid: 8807762
Pang SC, Tan RY, Choke E, Ho J, Tay KH, Gogna A, et al. SlroliMus coated angioplasty versus plain balloon angioplasty in the tREatment of dialySis access dysfunctION (IMPRESSION): study protocol for a randomized controlled trial. Trials. 2021;22(1):945.
doi: 10.1186/s13063-021-05920-3
pubmed: 34930401
pmcid: 8687634
Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.
doi: 10.1136/bmj.e7586
pubmed: 23303884
pmcid: 3541470
Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics. 1986;42(3):507–19.
doi: 10.2307/2531201
pubmed: 3567285
Richarz S, Greenwood S, Kingsmore DB, Thomson PC, Dunlop M, Bouamrane MM, et al. Validation of a vascular access specific quality of life measure (VASQoL). J Vasc Access. 2021;24(4):702–14.
doi: 10.1177/11297298211046746
pubmed: 34608832